Literature DB >> 15255125

Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.

Jeffrey S Dlott1, Constance F M Danielson, Deborah E Blue-Hnidy, Leo J McCarthy.   

Abstract

An extensive variety of drugs have been associated with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP/HUS). Although a direct causal effect has usually not been proven, the cumulative evidence linking several drugs with TTP/HUS is strong. This paper reviews several categories of drugs including antineoplastics, immunotherapeutics and anti-platelet agents that have been reported to induce TTP/HUS. The pathogenesis of drug-induced TTP/HUS and the effectiveness of treatment regimens are also reviewed. A consensus on diagnostic criteria to accurately and consistently diagnose drug-induced TTP is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15255125     DOI: 10.1111/j.1526-0968.2003.00127.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  25 in total

1.  Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome.

Authors:  Philipp A Lang; Ortraud Beringer; Jan P Nicolay; Oliver Amon; Daniela S Kempe; Tobias Hermle; Philipp Attanasio; Ahmad Akel; Richard Schäfer; Björn Friedrich; Teut Risler; Matthias Baur; Christoph J Olbricht; Lothar Bernd Zimmerhackl; Peter F Zipfel; Thomas Wieder; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2006-04-19       Impact factor: 4.599

2.  Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature.

Authors:  Arife Ulas; Kamile Silay; Sema Akinci; Muhammed Bulent Akinci; Mehmet Ali Sendur; Didem Sener Dede; Yunus Halil Polat; Bulent Yalcin
Journal:  Oncol Lett       Date:  2015-06-08       Impact factor: 2.967

3.  Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005.

Authors:  K G J Pollock; D Young; T J Beattie; W T A Todd
Journal:  Epidemiol Infect       Date:  2007-03-05       Impact factor: 2.451

4.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 5.  Thrombotic microangiopathy with targeted cancer agents.

Authors:  John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

6.  Induction of eryptosis by cyclosporine.

Authors:  Olivier M Niemoeller; Ahmad Akel; Philipp A Lang; Philipp Attanasio; Daniela S Kempe; Tobias Hermle; Malgorzata Sobiesiak; Thomas Wieder; Florian Lang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-22       Impact factor: 3.000

Review 7.  Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Nephrol       Date:  2013-08-06

8.  Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report.

Authors:  Keith Siau; Mohini Varughese
Journal:  Med Oncol       Date:  2009-10-22       Impact factor: 3.064

9.  [A 42 year old patient with bilateral loss of sight and hypertension. Gemcitabine-associated thrombotic microangiopathy (TMA)].

Authors:  A Schmidt; N Schwella; U Helmchen; D von Renteln; K Caca
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

Review 10.  Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.

Authors:  R H Aster; B R Curtis; J G McFarland; D W Bougie
Journal:  J Thromb Haemost       Date:  2009-04-02       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.